Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes.
R'EHPAD
Determination of the Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes in Franche-Comté (France).
1 other identifier
interventional
264
1 country
1
Brief Summary
This study evaluates individual and collective factors of ESBL and CRE carriage in nursing homes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2017
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 2, 2017
CompletedFirst Posted
Study publicly available on registry
August 15, 2017
CompletedStudy Start
First participant enrolled
November 20, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 26, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 26, 2018
CompletedDecember 6, 2018
March 1, 2018
7 months
August 2, 2017
December 5, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
ESBL and CRE carriage
number of residents colonized with a extented-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL) or carbapenem-resistant Enterobacteriaceae (CRE)
the day of the study
Secondary Outcomes (1)
patient and establishment factors associated with ESBL and CRE carriage with a questionnaire
the day of the study
Study Arms (1)
Experimental
EXPERIMENTALrealization of a rectal swab or stool sample for all the résidents included in the study.
Interventions
Eligibility Criteria
You may qualify if:
- voluntary residents present in the institution on the study day
You may not qualify if:
- dement-wandering resident
- unlikely to cooperate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Besançon
Besançon, 25000, France
Study Officials
- PRINCIPAL INVESTIGATOR
Céline C Bouvier-Slekovec, Dr
CHU de Besançon
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 2, 2017
First Posted
August 15, 2017
Study Start
November 20, 2017
Primary Completion
June 26, 2018
Study Completion
June 26, 2018
Last Updated
December 6, 2018
Record last verified: 2018-03
Data Sharing
- IPD Sharing
- Will not share